These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38171711)

  • 1. Inhalable Therapies for the Heart: Take the "Lung" Way Home?
    Hulot JS; Kupatt C
    J Am Coll Cardiol; 2024 Jan; 83(1):60-62. PubMed ID: 38171711
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhalable particulate drug delivery systems for lung cancer therapy: Nanoparticles, microparticles, nanocomposites and nanoaggregates.
    Abdelaziz HM; Gaber M; Abd-Elwakil MM; Mabrouk MT; Elgohary MM; Kamel NM; Kabary DM; Freag MS; Samaha MW; Mortada SM; Elkhodairy KA; Fang JY; Elzoghby AO
    J Control Release; 2018 Jan; 269():374-392. PubMed ID: 29180168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of an inhalable, stimuli-responsive particulate system for delivery to deep lung tissue.
    Abbas Y; Azzazy HM; Tammam S; Lamprecht A; Ali ME; Schmidt A; Sollazzo S; Mathur S
    Colloids Surf B Biointerfaces; 2016 Oct; 146():19-30. PubMed ID: 27244047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel therapeutic outlook: Classification, applications and challenges of inhalable micron/nanoparticle drug delivery systems in lung cancer (Review).
    Xie L; Xie D; Du Z; Xue S; Wang K; Yu X; Liu X; Peng Q; Fang C
    Int J Oncol; 2024 Apr; 64(4):. PubMed ID: 38391039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formulation and clinical perspectives of inhalation-based nanocarrier delivery: a new archetype in lung cancer treatment.
    Bardoliwala D; Javia A; Ghosh S; Misra A; Sawant K
    Ther Deliv; 2021 May; 12(5):397-418. PubMed ID: 33902294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of Optimized, Inhalable, Gemcitabine-Loaded Gelatin Nanocarriers for Lung Cancer.
    Youngren-Ortiz SR; Hill DB; Hoffmann PR; Morris KR; Barrett EG; Forest MG; Chougule MB
    J Aerosol Med Pulm Drug Deliv; 2017 Oct; 30(5):299-321. PubMed ID: 28277892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation and properties of inhalable nanocomposite particles for treatment of lung cancer.
    Tomoda K; Ohkoshi T; Hirota K; Sonavane GS; Nakajima T; Terada H; Komuro M; Kitazato K; Makino K
    Colloids Surf B Biointerfaces; 2009 Jul; 71(2):177-82. PubMed ID: 19264458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting sialic acid residues on lung cancer cells by inhalable boronic acid-decorated albumin nanocomposites for combined chemo/herbal therapy.
    Elgohary MM; Helmy MW; Abdelfattah EA; Ragab DM; Mortada SM; Fang JY; Elzoghby AO
    J Control Release; 2018 Sep; 285():230-243. PubMed ID: 30009892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhalable nanostructured lipid particles of 9-bromo-noscapine, a tubulin-binding cytotoxic agent: in vitro and in vivo studies.
    Jyoti K; Kaur K; Pandey RS; Jain UK; Chandra R; Madan J
    J Colloid Interface Sci; 2015 May; 445():219-230. PubMed ID: 25622047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhalable bioresponsive chitosan microspheres of doxorubicin and soluble curcumin augmented drug delivery in lung cancer cells.
    Jyoti K; Pandey RS; Kush P; Kaushik D; Jain UK; Madan J
    Int J Biol Macromol; 2017 May; 98():50-58. PubMed ID: 28130133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced therapeutic inhalation aerosols of a Nrf2 activator and RhoA/Rho kinase (ROCK) inhibitor for targeted pulmonary drug delivery in pulmonary hypertension: design, characterization, aerosolization,
    Acosta MF; Muralidharan P; Grijalva CL; Abrahamson MD; Hayes D; Fineman JR; Black SM; Mansour HM
    Ther Adv Respir Dis; 2021; 15():1753466621998245. PubMed ID: 33719747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhalable multi-compartmental phospholipid enveloped lipid core nanocomposites for localized mTOR inhibitor/herbal combined therapy of lung carcinoma.
    Kabary DM; Helmy MW; Abdelfattah EA; Fang JY; Elkhodairy KA; Elzoghby AO
    Eur J Pharm Biopharm; 2018 Sep; 130():152-164. PubMed ID: 29964122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The next generation therapy for lung cancer: taking medicine by inhalation.
    Wang Z; Liu Z; Mei J; Xu S; Liu Y
    Nanotechnology; 2021 Jul; 32(39):. PubMed ID: 34167099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interface-Enrichment-Induced Instability and Drug-Loading-Enhanced Stability in Inhalable Delivery of Supramolecular Filaments.
    Anderson CF; Chakroun RW; Su H; Mitrut RE; Cui H
    ACS Nano; 2019 Nov; 13(11):12957-12968. PubMed ID: 31651153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of inhalable quinacrine loaded bovine serum albumin modified cationic nanoparticles: Repurposing quinacrine for lung cancer therapeutics.
    Vaidya B; Kulkarni NS; Shukla SK; Parvathaneni V; Chauhan G; Damon JK; Sarode A; Garcia JV; Kunda N; Mitragotri S; Gupta V
    Int J Pharm; 2020 Mar; 577():118995. PubMed ID: 31935471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matrix metalloproteinase 2/9-triggered-release micelles for inhaled drug delivery to treat lung cancer: preparation and in vitro/in vivo studies.
    Wang X; Chen Q; Zhang X; Ren X; Zhang X; Meng L; Liang H; Sha X; Fang X
    Int J Nanomedicine; 2018; 13():4641-4659. PubMed ID: 30147314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Particle engineering for pulmonary drug delivery.
    Chow AH; Tong HH; Chattopadhyay P; Shekunov BY
    Pharm Res; 2007 Mar; 24(3):411-37. PubMed ID: 17245651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization and aerosol dispersion performance of advanced spray-dried chemotherapeutic PEGylated phospholipid particles for dry powder inhalation delivery in lung cancer.
    Meenach SA; Anderson KW; Zach Hilt J; McGarry RC; Mansour HM
    Eur J Pharm Sci; 2013 Jul; 49(4):699-711. PubMed ID: 23707466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib Loaded Inhalable Polymeric Nanocarriers against Non-Small Cell Lung Cancer.
    Shukla SK; Kulkarni NS; Farrales P; Kanabar DD; Parvathaneni V; Kunda NK; Muth A; Gupta V
    Pharm Res; 2020 Mar; 37(3):67. PubMed ID: 32166411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhalation delivery of topotecan is superior to intravenous exposure for suppressing lung cancer in a preclinical model.
    Kuehl PJ; Grimes MJ; Dubose D; Burke M; Revelli DA; Gigliotti AP; Belinsky SA; Tessema M
    Drug Deliv; 2018 Nov; 25(1):1127-1136. PubMed ID: 29779406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.